Heart failure (HF) is a chronic clinical syndrome involving up to 6.5 million people in Europe. It is the leading cause of hospitalisation in adults, yielding a healthcare cost of 17 billion euro/year. The mortality is comparable/superior to several type of cancers in the EU perspective, reaching 70% at 5-year in the advanced stages of HF. European Society of Cardiology (ESC) recently updated the HF guidelines to incorporate two new drug classes showing a dramatic reduction of hospitalisation and death in large scale randomised clinical trials (RCT) involving patients with heart failure and reduced ejection fraction (HFrEF).

6.5 milion involved people in Europe with heart failure and reduced ejection fraction


The conceptual framework of BIOTOOL-CHF will be developed into three main PHASES:

BIOTOOL-CHF will discover a multiparametric biomarker-based score, integrating clinical profiles, novel and standard laboratory assays, to define independent clusters of congestion predicting congestion-related events, including worsening heart failure as well as toxicities related to excessive diuretic therapy
In this phase BIOTOOL-CHF will direct the activities towards the development of two products of potential industrial exploitation
BIOTOOL-CHF will provide clinical validation of the biomarkers-guided approach to manage diuretic therapy by a prospective randomised study comparing standard of care with decision-making tool guided approach